Elevation Oncology Inc ELEV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ELEV is a good fit for your portfolio.
News
-
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
-
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
-
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
-
Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors
-
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm
-
Elevation Oncology to Participate in Upcoming Investor Conferences
-
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
-
Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors
Trading Information
- Previous Close Price
- $4.01
- Day Range
- $3.75–4.07
- 52-Week Range
- $0.36–5.89
- Bid/Ask
- $3.51 / $4.05
- Market Cap
- $184.87 Mil
- Volume/Avg
- 990,269 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
Valuation
|
Metric
|
ELEV
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.10 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ELEV
|
|---|---|
Quick Ratio | 20.05 |
Current Ratio | 21.22 |
Interest Coverage | −10.80 |
Quick Ratio
ELEV
Profitability
|
Metric
|
ELEV
|
|---|---|
Return on Assets (Normalized) | −41.48% |
Return on Equity (Normalized) | −71.70% |
Return on Invested Capital (Normalized) | −46.07% |
Return on Assets
ELEV
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Plsprjzb | Mpf | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gwzjzqk | Xvvyzcr | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Npgmtlmg | Vwrscc | $98.1 Bil | |
MRNA
| Moderna Inc | Chsprgwv | Dmts | $39.1 Bil | |
ARGX
| argenx SE ADR | Qxgkdspq | Rpvrh | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Clcjjfsss | Glk | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jcbbpbjmq | Ztskbx | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ztzsvqdj | Kmpdl | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ytmsvscfsj | Kbsbtx | $12.5 Bil | |
INCY
| Incyte Corp | Lzyfwrf | Xfsknm | $11.9 Bil |